News Daily News Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF L.A. McKeown December 07, 2021
News Conference News AHA 2021 Canagliflozin Improves Quality of Life in HF Patients Michael O'Riordan November 16, 2021
News Conference News AHA 2021 Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE Shelley Wood November 14, 2021
News Features Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle Shelley Wood October 08, 2021
News Conference News HFSA 2021 PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF Todd Neale September 13, 2021
News Conference News ESC 2021 New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT Shelley Wood August 28, 2021
News Conference News ESC 2021 EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF Todd Neale August 27, 2021
News Daily News FDA Green-lights Empagliflozin for HF With Reduced Ejection Fraction Michael O'Riordan August 19, 2021
News Daily News Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results Todd Neale July 06, 2021
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for June 2021 Shelley Wood July 05, 2021
News Daily News Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care Shelley Wood May 27, 2021
News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021